Almost every week on this blog, at least several people discuss the stock prices of hair loss companies that are publicly traded. I have wanted to write this post for many years, but there were some issues that prevented me from doing so:
- Is it worth covering companies such as Allergan, for whom hair loss related products represent a tiny fraction of overall revenues? i.e., unless they come out with a truly game-changing hair loss product, their stock price will never be affected significantly by any new minor hair research developments.
- Does it make sense to include the numerous companies working on alopecia areata (AA) related treatments? The vast majority (over 95 percent) of hair loss patients are suffering from androgenetic alopecia (AGA).
- What about pharmaceutical companies working on generic or topical versions of products such as finasteride or dutasteride? Especially if these products represent a small portion of their overall revenues?
- How about manufacturers of somewhat controversial products such as low-level laser therapy (LLLT) devices?
Hair Loss Companies
For the time being, I have decided to only include companies that I think are of most relevance to our ultimate goal of a hair loss cure. Perhaps I will modify this in future. Especially if a company develops a moderately effective hair loss product that accounts for a large share of its total sales.
Some currently privately-held companies (e.g., Fidia, Follica, Histogen and Samumed) will be added to the below list if they go public in the future.
It seems like we regularly see situations where a company makes a big positive announcement about its hair loss product development, only to see little change in its stock price movement. Or sometimes even an unexpected decline in its share price despite the good news. The finance experts among this blog’s readers can try to explain such developments each time they occur.
Aclaris Therapeutics (ACRS) — perhaps of most interest to us in 2018. Fast moving relatively new US-based company that is working on both AA and AGA treatments.
Allergan (AGN) — working on a number of hair loss products such as Bimatoprost and Setipiprant. Hair loss segment accounts for a small portion of overall sales. Headquartered in Ireland.
Cassiopeia (SKIN:SW) — its Breezula (formerly CB-03-01) product is causing some excitement this year per one of my industry contacts.
Follicum (FOLLI:SS) — highly professional Swedish company, with its main area of focus being on its hair regrowth product.
PolarityTE (COOL) — only a matter of time before this US-based company develops a hair loss product. Extremely fast moving new company with highly experienced and qualified key staff members.
PureTech Health (PRTC) — Although headquartered in the US, they are listed on the London Stock Exchange. Their hair loss sector is represented by Follica, which has been teasing us for over a decade.
RepliCel (REPCF) — a Canadian company that has been in the news in the hair loss world for a decade. Replicel’s drastically larger Japanese partner Shiseido (see below) is of much more interest to us when it comes to a hair loss treatment. However, for speculators and day traders, Replicel may be an interesting play.
Shiseido (SSDOY) — a Japanese cosmetics behemoth that is especially significant in Asia. Basic hair loss shampoos and other related products represent a major portion of their overall sales. Besides working on a hair loss cure based on its own technology, Shiseido also holds rights to Replicel’s technology in Asia.